The first 18 months of tezepelumab in real-life practice: Characteristics of patients commenced and efficacy in a nationwide, complete cohort of patients with severe asthma - Amsterdam 2025

Real-world lessons on biologic use in asthma

Chair(s): Hitasha Rupani, Martina Zappa

Session type: Poster session

The first 18 months of tezepelumab in real-life practice: Characteristics of patients commenced and efficacy in a nationwide, complete cohort of patients with severe asthma

Marianne Baastrup Soendergaard

EVENTS HOME

Abstract

Previous presentation

Next presentation

Session content

A real-world study of tezepelumab in severe asthmatics of a French cohort.

Malo Bouguennec

Poster

Abstract

Early and continued improvements in asthma control in patients with severe, uncontrolled asthma after tezepelumab initiation: real-world ASCENT study

Katrin Milger-kneidinger

Poster

Abstract

Sex Differences in Response to Biologic Therapy for Severe Asthma

Francesca Sala

Poster

Abstract

Upper airway and quality of life improvements with dupilumab treatment for severe asthma in the Danish Severe Asthma Registry

Andreas Lillieroth Bricaud

Poster

Abstract

Do biological therapies reduce emergency asthma presentations to a teaching hospital in the East of England.

Joyce Oi Suet Cheng

Poster

Abstract

Gender differences in the 6-month response to tezepelumab treatment in patients with severe asthma.

Maria Lisa Baccellieri

Poster

Abstract

Real life evidence with biologics in severe asthma in 5 years.

Cristina Barea Jimenez

Poster

Abstract

GALERNA study: long-term evolution of exacerbations, hospitalizations and emergency room visits in patients with severe eosinophilic asthma receiving benralizumab in a real-world setting

Ismael García Moguel

Poster

Abstract

Real-world Impact of Tezepelumab in Severe Asthma: insights from the ADVANCAT Study (Advancing Severe Asthma Care with Tezepelumab in Catalonia)

Ebymar Arismendi

Poster

Abstract

Health-related quality of life (HRQoL) in patients with severe asthma treated with mepolizumab in Arab Gulf countries

Bassam Mahboub

Poster

Abstract

REAL LIFE EXPERIENCE AT THE INFANTA ELENA COMARCAL HOSPITAL AFTER 24 WEEKS OF TREATMENT WITH TEZEPELUMAB

Isabel Muñoz Ramirez

Poster

Abstract

The first 18 months of tezepelumab in real-life practice: Characteristics of patients commenced and efficacy in a nationwide, complete cohort of patients with severe asthma

Marianne Baastrup Soendergaard

Abstract

The impact of biologics on lung function parameters: a comparative analysis

Angelica Tiotiu Cepuc

Poster

Abstract

Eosinophilic adverse reactions associated with different biologics targeting type 2 inflammation: a disproportionality analysis of the Food and Drug Administration Adverse Event Reporting System (FAERS)

Chun Chang

Poster

Abstract

Mepolizumab in severe asthma: Turkish real-world data from a bi-directional, self-controlled study

Sevim Bavbek

Poster

Abstract

The Impact of Inhaled Corticosteroid Use on the Effectiveness of Tezepelumab in Severe Asthma

Grainne D'ancona

Poster

Abstract

Real- world evidence of Tezepelumab for severe asthma - a retrospective multicenter cohort

Ophir Freund

Poster

Abstract

Response after one year of treatment with Benralizumab

Aureliano Ais-daza

Poster

Abstract

Real world one year outcomes for severe asthma patients on tezepelumab

Lynn Elsey

Poster

Abstract

Real world evidence of administration of biologic agents in patients with severe asthma: an analysis of the Respiratory Department of University Hospital of Patras

Ourania Papaioannou

Poster

Abstract

CDN Connection Issue

The ERS Congress 2025, Amsterdam

#{title}